

# PMOS EXHIBIT 2

EXHIBIT 7 OF RYAN DIETZ'S  
DECEMBER 6, 2018 DEPOSITION:  
PLAINTIFF'S LAB NOTEBOOK PAGES

3 - 74

BOOK PAGE





TITLE/TITRE/TITEL IPs Project

PROJECT/PROJET/PROJEKT

Continued From Page/Suite de la page/ Fortsetzung von Seite:

I'm planning a project to see if ~~transient~~ transient transfection of Yamashita factor T7 transcripts can induce iPS in MSC or perhaps MEF cultures. I've designed nested primers to make T7 templates for runoff transcription for the four Y factors + eGFP from an IRES2-eGFP Clontech plasmid Ra' gave me. Also, I've designed Q primers targeting the 3' UTR of the endogenous transcripts for the Y factors, so we can monitor if the pluripotency circuit is activated during or after transfection. I envision changing the media for the cells every day, using media spiked with the T7 RNA cocktail, and perhaps collecting cells for Q analysis every ~3 days at passage. Mins TransIT or HT Transfection look like the best bets for the

GFP-IF TAATACGACTCACTATAGGTTTCTTTGAAAAACAGATGA  
GFP-IR CAATGTGGTATGGCTGATTATG  
GFP-OF TCGGTGCACATGCTTTACAT  
GFP-OR GGGAGGTGTGGGAGTTT  
KLF-IF TAATACGACTCACTATAGGATTAATGAGGACGACCTG  
KLF-IR TGTGGTCACATCCACTCG  
KLF-OF GGCTCAGTACCCCTCTCTC  
KLF-OR CTCGTGGGAGACAGTGTGA  
KLF-OF ATGCCCGGACTTACAAAATG  
KLF-OR CCCCAGGCTCACTGATTTA  
MYC-IF TAATACGACTCACTATAGGAGAGCTCTCGAGCTGTTG  
MYC-IR TCAGCTCTCTCTCGAGTTA  
MYC-OF GGACAGTGTCTCTGCTCTG  
MYC-OR AATTCAGCGCATCATCT  
MYC-OF GCATGCTCAAAGCTTAACCT  
MYC-OR GGCAGTAAATTTATGGCTGAA  
OCT-IF TAATACGACTCACTATAGGAGAGCTCTCTTCCACAG  
OCT-IR TGCTACCTCCTTGCCTTG  
OCT-OF GTCCCTAGGTGAGCGCTCT  
OCT-OR CCACCTCTGTTGTGCTTTA  
OCT-OF GGATGGGAAAGAGCTCAG  
OCT-OR GAACAAATGATCAGTGACAGACA  
SOX-IF TAATACGACTCACTATAGGACTATTCTCCGACATCTCC  
SOX-IR TCTCCAGTTCGAGTCCAG  
SOX-OF GTCTCAGCTCCGCTCC  
SOX-OR CCTCCCAATTCCTTGAT  
SOX-OF TTAACGCAAAACCGTGATG  
SOX-OR AGTCCCCCAAAAGAGTCC



Continued To Page/à la page/Fortsetzung bis Seite:

SIGNATURE/UNTERSCHRIFT 	DATE/DATUM 6/27/09	PROPRIETARY INFORMATION BELONGING TO L'INFORMATION DE PROPRIÉTÉ INDUSTRIELLE APPARTENANT À EGENE INFORMATIONEN VON
DISCLOSED TO AND UNDERSTOOD BY: LU ET APPROUVE PAR: ÜBERPRÜFT UND FREIGEgeben DURCH:	DATE/DATUM 4/30/09	

DrZ  
EXHIBIT NO. 7  
MCL 12/6/18

3 -112

BOOK PAGE

TITLE/TITRE/TITEL IPS Project

PROJECT/PROJET/PROJEKT

Continued From Page/Suite de la page/ Fortsetzung von Seite:

Discussed IPS project with Derrick and got okay to proceed, as long as expenditures remain modest. Idea is to try and convert MEFs into IPS by repeated transfection of Yamanaka factor-encoding synthetic mRNAs over a 10-14 day time course. Plan to PCR up the T7 templates from murine ES RNA using the primers I have already purchased (p.85). I'll use Ambion's MESSAGE machine to make capped, polyadenylated transcript and (most likely) TransIT to facilitate daily transfection by direct administration of RNA + cationic reagent to culture medium. Will use eGFP mRNA to optimize transfection conditions and probably also to monitor transfection efficiency during experiment. Derrick recommends using eGFP RNA at substantially lower concentration than the Y factor RNA in these trials. Also, he said we should definitely go with MEFs for the initial experiment, not iSCs, since they are a known quantity w.r.t. to IPS generation. If we see ES like colonies, we should take them to blastocyst injection immediately to validate pluripotency. For this purpose, we need reporter cells. I will order a ROSA26 (Kaz2) mouse (male, breeding age i.e. 10-12 wts) so we can get appropriate MEFs. As soon as mouse arrives, mate to two B6 females. Check for vaginal plugs (signifying pregnancy) and wait 13 days before recovering embryos to make MEFs. ~~We~~ Will need to check for ROSA26 heterozygosity by  $\beta$ -Gal staining of tissue samples - we only want ROSA26<sup>+</sup> MEFs for the experiment. Once embryos are recovered, mate the ROSA26 again to produce replacement animals should this mouse die.

Want to try 5-azadeoxycytidine and Valproic acid as adjuncts to IPS generation in this experiment. Reagents are available from VWR.

Needs:

- 5-azadeoxycytidine
- Valproic acid
- MESSAGE machine Ultra

Continued To Page/à la page/Fortsetzung bis Seite:

SIGNATURE/UNTERSCHRIFT

DATE/DATUM

7/19/09

PROPRIETARY INFORMATION BELONGING TO  
L'INFORMATION DE PROPRIÉTÉ INDUSTRIELLE APPARTENANT À  
EIGENE INFORMATIONEN VONDISCLOSED TO AND UNDERSTOOD BY:  
LU ET APPROUVE PAR:  
ÜBERPRÜFT UND FREIGEgeben DURCH:


DATE/DATUM

Dht 4/30/09



TITLE/TITRE/TITEL T+24 HRS FACS PROJECT/PROJET/PROJEKT iPS

Continued From Page/Suite de la page/ Fortsetzung von Seite:




Sample	Ancestry Subset Value Type For	live Freq. o...	live GFP+ Freq. o...	live GFP+ Geom. ... FL1-H...	live GFP+ Mean FL1-H...	live GFP+ Freq. o...	live GFP+ Geom. ... FL1-H...	live GFP+ Mean FL1-H...
1: No RNA		22.5	0.65	25.3	26	99.4	6.29	6.71
2: mScript RNA		27.8	65.1	78.2	132	34.9	8.27	9.12
3: No Mods		26.3	63.7	129	268	36.3	7.3	8.07
4: Psi		25.7	75.1	165	342	24.9	7.51	8.35
5: SmC		25.7	73.1	200	428	26.9	7.64	8.35
6: SmU		24	59.7	135	297	40.3	7.13	7.84
7: SmC-SmU		24.2	61.7	99.4	182	38.3	7.45	8.27
8: SmC-Psi		21.6	76.6	210	425	23.4	7.37	8.12
9: CIP		27.3	46.2	77.6	145	53.8	6.69	7.49
10: TdI		27.5	46.4	105	230	53.6	6.67	7.36
11: No Treatment 1		27.9	0.14	24.5	25.2	99.9	3.19	3.45
12: No Treatment 2		28.3	0.15	23.2	23.6	98.8	3.42	3.7
Mean		25.8	57.4	108	259	52.6	6.88	7.23
StdDev		2.38	30	61.8	147	80	1.82	1.81

SmC-~~4~~ looks like the winner here, with SmC & 4 alone close behind. There hasn't been much of a falloff vs +24 HRS across the board, but No Mods has done a bit worse in this respect than the SmC/4 and mScript wells. (See p.23). I stalled with PI, but again haven't tried to comp here. Settings for PMTs were same as for +24 hrs:

FSC E00 1 Lin FL1 431 Log FL3 650 1 Lin  
SSC 350 1 Lin FL2 6113 Lin

No treatment cells ran maybe 40% faster than sorted, suggesting there has been some cell death in treated wells.

Continued To Page/a la page/Fortsetzung bis Seite:

SIGNATURE/UNTERSCHRIFT 	DATE/DATUM 11/2/08	PROPRIETARY INFORMATION BELONGING TO L'INFORMATION DE PROPRIÉTÉ INDUSTRIELLE APPARTENANT À EGENE INFORMATIONEN VON
DISCLOSED TO AND UNDERSTOOD BY: LU ET APPRÉHENSÉ PAR: ÜBERPRÜFT UND FREIGEgeben DURCH:	DATE/DATUM Dh2 4/29/09	

2 - 57  
BOOK PAGE

TITLE/TITRE/TITEL

PROJECT/PROJET/PROJEKT

Continued From Page/Suite de la page/ Fortsetzung von Seite:

wells show dose-dependent brightness relationship. Does look like only about half the cells are expressing significant GFP - similar to MEF experience.

T6 plate: Looks good for B18R. Hasn't been too much change since yesterday. In the B18R+ wells, only the most aggressively dosed (2-4-8-16) well is close to being trashed, and even that has quite a few small clusters. Cell density in the other B18R+ wells is poor, but not terrible. GFP expression still looks fair, esp in the lower dose wells - maybe a 4 or even better in the 2-2-2, 2-2-2 wells. B18R- wells look terrible - huge numbers of floaters (though there are quite a few in the B18R+ wells too), still a few small islands of cells, but with very feeble GFP expression. Minimal photostuff now across the whole plate.

Should take ~~all~~ these cultures to FACS ~~today~~, if possible.

12:00 AM FACSed the BJ plate. By eye, GFP expression looked down by maybe a factor of 2 relative to 6:45 AM check. See p.63 for FACS data.

4:50 PM Very faint GFP in B18R+, none in B18R-. We terminated transfections. Looks like we got ~6 days decent GFP expression in B18R+ wells, ~4 days in B18R- (4.5 perhaps). Lot of toxicity all around, but considerably worse in B18R- wells.

5:30 AM Set 4 x 12-well plates of HEK, ~10K per well, in HEK media (no Matrigel). Added a thawed vial of cells to 3ml media in a 14 ml tube, used 1ml syringe to dispense 40 µl aliquots.  $40 \mu l \div (1000 \div 5000) \times 10^6 = 10^4$  cells.)

FRI 3/30

4:00 PM

Pooled and split BJ2 from remaining 10 cm plate and 6-well to 2 x 15 cm dishes

In T6 plate, wells 1-3 show significant central islands, 4 is pretty trashed. All B18R- wells are trashed except one of the 2-2-4 replicates. All wells show more cellularity at the edge of the well. Phenotypes abundant, reminiscent of earlier, late-stage hTF trials.

Continued To Page/à la page/Fortsetzung bis Seite:

SIGNATURE/UNTERSCHRIFT

DATE/DATUM

1/29/09

PROPRIETARY INFORMATION BELONGING TO  
L'INFORMATION DE PROPRIÉTÉ INDUSTRIELLE APPARTENANT À  
EGERE INFORMATIONEN VONDISCLOSED TO WHO/À QUEL TOUJOURS BY:  
LU ET APPROUVÉ PAR:  
ÜBERPRÜFT UND FREIGEgeben DURCH:

DATE/DATUM

4/29/09